TLR4 signalling in the intestine in health and disease.

The colonic epithelium is lined along its apical membrane with approximately 10(14) bacteria/g of tissue. Commensal bacteria outnumber mammalian cells in the gut severalfold. The reason for this degree of commensalism probably resides in the recent recognition of the microbiome as an important source of metabolic energy in the setting of poorly digestible nutrients. As in many themes in biology, the host may have sacrificed short-term benefit, i.e. nutritional advantages, for long-term consequences, such as chronic inflammation or colon cancer. In the present review, we examine the role of TLR (Toll-like receptor) signalling in the healthy host and the diseased host. We pay particular attention to the role of TLR signalling in idiopathic IBD (inflammatory bowel disease) and colitis-associated carcinogenesis. In general, TLR signalling in health contributes to homoeostatic functions. These include induction of antimicrobial peptides, proliferation and wound healing in the intestine. The pathogenesis of IBD, ulcerative colitis and Crohn's disease may be due to increased TLR or decreased TLR signalling respectively. Finally, we discuss the possible role of TLR signalling in colitis-associated neoplasia.

[1]  H. Adami,et al.  Ulcerative colitis and colorectal cancer. A population-based study. , 1990, The New England journal of medicine.

[2]  R. Goldberg,et al.  Colorectal cancer prognosis among patients with inflammatory bowel disease. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[3]  M. Gazouli,et al.  Association between polymorphisms in the Toll-like receptor 4, CD14, and CARD15/NOD2 and inflammatory bowel disease in the Greek population. , 2005, World journal of gastroenterology.

[4]  S. Sugie,et al.  Dose-dependent promoting effect of dextran sodium sulfate on mouse colon carcinogenesis initiated with azoxymethane. , 2005, Histology and histopathology.

[5]  M. Abreu,et al.  Decreased Expression of Toll-Like Receptor-4 and MD-2 Correlates with Intestinal Epithelial Cell Protection Against Dysregulated Proinflammatory Gene Expression in Response to Bacterial Lipopolysaccharide1 , 2001, The Journal of Immunology.

[6]  F. Bäckhed,et al.  Host-Bacterial Mutualism in the Human Intestine , 2005, Science.

[7]  T. Ohkusa,et al.  Dysplasia and carcinoma development in a repeated dextran sulfate sodium‐induced colitis model , 2002, Journal of gastroenterology and hepatology.

[8]  C. Rao,et al.  Chemopreventive properties of a selective inducible nitric oxide synthase inhibitor in colon carcinogenesis, administered alone or in combination with celecoxib, a selective cyclooxygenase-2 inhibitor. , 2002, Cancer research.

[9]  J. Weisburger,et al.  Colon carcinogenesis with azoxymethane and dimethylhydrazine in germ-free rats. , 1975, Cancer research.

[10]  R. Xu,et al.  Toll-like receptor-4 is required for intestinal response to epithelial injury and limiting bacterial translocation in a murine model of acute colitis. , 2005, American journal of physiology. Gastrointestinal and liver physiology.

[11]  J. Weisburger,et al.  Colon carcinogenesis in germ-free rats with intrarectal 1,2-dimethylhydrazine and subcutaneous azoxymethane. , 1976, Cancer research.

[12]  Takuji Tanaka,et al.  Strain differences in the susceptibility to azoxymethane and dextran sodium sulfate-induced colon carcinogenesis in mice. , 2006, Carcinogenesis.

[13]  P. Rutgeerts,et al.  Toll‐like receptor‐1, ‐2, and ‐6 polymorphisms influence disease extension in inflammatory bowel diseases , 2006, Inflammatory bowel diseases.

[14]  D. Podolsky,et al.  Gamma Interferon Augments the Intracellular Pathway for Lipopolysaccharide (LPS) Recognition in Human Intestinal Epithelial Cells through Coordinated Up-Regulation of LPS Uptake and Expression of the Intracellular Toll-Like Receptor 4-MD-2 Complex , 2003, Infection and Immunity.

[15]  Yu-Tseung Liu,et al.  Maintenance of colonic homeostasis by distinctive apical TLR9 signalling in intestinal epithelial cells , 2006, Nature Cell Biology.

[16]  K. Van Steen,et al.  Deficient host-bacteria interactions in inflammatory bowel disease? The toll-like receptor (TLR)-4 Asp299gly polymorphism is associated with Crohn’s disease and ulcerative colitis , 2004, Gut.

[17]  P. Jänne,et al.  Chemoprevention of colorectal cancer. , 2000, The New England journal of medicine.

[18]  H. Leufkens,et al.  5-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study , 2005, Gut.

[19]  S. Akira,et al.  Adjuvant-Mediated Tumor Regression and Tumor-Specific Cytotoxic Response Are Impaired in MyD88-Deficient Mice , 2004, Cancer Research.

[20]  H. Cooper,et al.  Clinicopathologic study of dextran sulfate sodium experimental murine colitis. , 1993, Laboratory investigation; a journal of technical methods and pathology.

[21]  T. Mussack,et al.  Polymorphisms of the lipopolysaccharide-signaling complex in inflammatory bowel disease: association of a mutation in the Toll-like receptor 4 gene with ulcerative colitis. , 2004, Clinical immunology.

[22]  P. Liberski,et al.  Differential activation of total and EGF receptor (EGF-R) tyrosine kinase (tyr-k) in the rectal mucosa in patients with adenomatous polyps, ulcerative colitis and colon cancer. , 1997, Hepato-gastroenterology.

[23]  Mitsunobu Sato,et al.  Toll-like receptor signaling in anti-cancer immunity. , 2003, The journal of medical investigation : JMI.

[24]  Jason M Doherty,et al.  Activated macrophages are an adaptive element of the colonic epithelial progenitor niche necessary for regenerative responses to injury. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[25]  D. Podolsky,et al.  Mechanisms of cross hyporesponsiveness to Toll-like receptor bacterial ligands in intestinal epithelial cells. , 2004, Gastroenterology.

[26]  R. Medzhitov,et al.  Regulation of Spontaneous Intestinal Tumorigenesis Through the Adaptor Protein MyD88 , 2007, Science.

[27]  L. Melton,et al.  Risk of intestinal cancer in inflammatory bowel disease: a population-based study from olmsted county, Minnesota. , 2006, Gastroenterology.

[28]  A. Kato,et al.  COX‐2, prostanoids and colon cancer , 2002 .

[29]  K. Michelsen,et al.  Human Intestinal Epithelial Cells Are Broadly Unresponsive to Toll-Like Receptor 2-Dependent Bacterial Ligands: Implications for Host-Microbial Interactions in the Gut 1 , 2003, The Journal of Immunology.

[30]  R. Xu,et al.  Cox-2 is regulated by Toll-like receptor-4 (TLR4) signaling: Role in proliferation and apoptosis in the intestine. , 2006, Gastroenterology.

[31]  B. Warner,et al.  Epidermal growth factor is critical for intestinal adaptation following small bowel resection , 2000, Microscopy research and technique (Print).

[32]  Hui Wang,et al.  Experimental therapy for colon cancer: anti-cancer effects of TLR9 agonism, combination with other therapeutic modalities, and dependence upon p53. , 2007, International journal of oncology.

[33]  S. Solomon,et al.  Celecoxib for the prevention of sporadic colorectal adenomas. , 2006, The New England journal of medicine.

[34]  S. Anant,et al.  Prostaglandin E2 reduces radiation-induced epithelial apoptosis through a mechanism involving AKT activation and bax translocation. , 2004, The Journal of clinical investigation.

[35]  K. Abrams,et al.  Colorectal cancer prevention in ulcerative colitis: a case‐control study , 2000, Alimentary pharmacology & therapeutics.

[36]  I. Azuma,et al.  Role of toll-like receptors and their adaptors in adjuvant immunotherapy for cancer. , 2003, Anticancer research.

[37]  R. DuBois,et al.  Review article: cyclooxygenase – a target for colon cancer prevention , 2000, Alimentary pharmacology & therapeutics.

[38]  Yibang Chen,et al.  Toll-like receptors on tumor cells facilitate evasion of immune surveillance. , 2005, Cancer research.

[39]  Alastair Forbes,et al.  Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. , 2004, Gastroenterology.

[40]  G. Rogler,et al.  Toll-like receptors 2 and 4 are up-regulated during intestinal inflammation. , 2001, Gastroenterology.

[41]  C. A. de la Motte,et al.  The Toll-interleukin-1 receptor member SIGIRR regulates colonic epithelial homeostasis, inflammation, and tumorigenesis. , 2007, Immunity.

[42]  Rajnish A. Gupta,et al.  Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2 , 2001, Nature Reviews Cancer.

[43]  R. DuBois,et al.  Cyclooxygenase 2-derived prostaglandin E2 regulates the angiogenic switch. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[44]  D. Palli,et al.  General and cancer specific mortality of a population based cohort of patients with inflammatory bowel disease: the Florence study , 1998, Gut.

[45]  Mark Tsang,et al.  Dual infection with Helicobacter bilis and Helicobacter hepaticus in p-glycoprotein-deficient mdr1a-/- mice results in colitis that progresses to dysplasia. , 2005, The American journal of pathology.

[46]  S. Itzkowitz Cancer prevention in patients with inflammatory bowel disease. , 2002, Gastroenterology clinics of North America.

[47]  K. Abrams,et al.  The risk of colorectal cancer in ulcerative colitis: a meta-analysis , 2001, Gut.

[48]  J. Gordon,et al.  Commensal Host-Bacterial Relationships in the Gut , 2001, Science.

[49]  Michael Karin,et al.  IKKβ Links Inflammation and Tumorigenesis in a Mouse Model of Colitis-Associated Cancer , 2004, Cell.

[50]  S. Itzkowitz,et al.  Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation. , 2004, American journal of physiology. Gastrointestinal and liver physiology.

[51]  R. Sartor,et al.  Resident Enteric Bacteria Are Necessary for Development of Spontaneous Colitis and Immune System Activation in Interleukin-10-Deficient Mice , 1998, Infection and Immunity.

[52]  A. Ekbom,et al.  Is colonoscopic surveillance reducing colorectal cancer mortality in ulcerative colitis? A population based case control study , 1998, Gut.

[53]  Ruslan Medzhitov,et al.  Recognition of Commensal Microflora by Toll-Like Receptors Is Required for Intestinal Homeostasis , 2004, Cell.

[54]  J. Wands,et al.  Enhanced colon tumor induction in uncoupling protein-2 deficient mice is associated with NF-kappaB activation and oxidative stress. , 2006, Carcinogenesis.

[55]  K. Uchida,et al.  Intestinal microflora are necessary for development of spontaneous adenocarcinoma of the large intestine in T-cell receptor beta chain and p53 double-knockout mice. , 2001, Cancer research.

[56]  S. Lippman,et al.  Cyclooxygenase-2 and epidermal growth factor receptor: pharmacologic targets for chemoprevention. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[57]  V. Steele,et al.  Mechanisms and applications of non-steroidal anti-inflammatory drugs in the chemoprevention of cancer. , 2003, Mutation research.

[58]  T. Hla,et al.  Overexpression of Cyclooxygenase-2 Is Sufficient to Induce Tumorigenesis in Transgenic Mice* , 2001, The Journal of Biological Chemistry.

[59]  M. Tsan Toll-like receptors, inflammation and cancer. , 2006, Seminars in cancer biology.

[60]  A. Malkinson,et al.  Toll-like receptor 4 in butylated hydroxytoluene-induced mouse pulmonary inflammation and tumorigenesis. , 2005, Journal of the National Cancer Institute.

[61]  J. Crusius,et al.  The toll-like receptor 4 (TLR4) Asp299Gly polymorphism is associated with colonic localisation of Crohn’s disease without a major role for the Saccharomyces cerevisiae mannan-LBP-CD14-TLR4 pathway , 2005, Gut.

[62]  J. Fox,et al.  CD4(+)CD25(+) regulatory lymphocytes require interleukin 10 to interrupt colon carcinogenesis in mice. , 2003, Cancer research.

[63]  D. Podolsky Mechanisms of regulatory peptide action in the gastrointestinal tract: trefoil peptides. , 2000, Journal of gastroenterology.

[64]  D. Podolsky,et al.  Differential Alteration in Intestinal Epithelial Cell Expression of Toll-Like Receptor 3 (TLR3) and TLR4 in Inflammatory Bowel Disease , 2000, Infection and Immunity.

[65]  M. Hornef,et al.  Postnatal acquisition of endotoxin tolerance in intestinal epithelial cells , 2006, The Journal of experimental medicine.

[66]  S. Pawlowski,et al.  Elimination of colon cancer in germ-free transforming growth factor beta 1-deficient mice. , 2002, Cancer research.

[67]  T. Kopp,et al.  Tumoricidal activity of TLR7/8-activated inflammatory dendritic cells , 2007, The Journal of experimental medicine.

[68]  T. Ohkusa,et al.  Occurrence of dysplasia and adenocarcinoma after experimental chronic ulcerative colitis in hamsters induced by dextran sulphate sodium. , 1992, Gut.

[69]  David Baltimore,et al.  Embryonic lethality and liver degeneration in mice lacking the RelA component of NF-κB , 1995, Nature.

[70]  H. Knutsen,et al.  Identification of flat dysplastic aberrant crypt foci in the colon of azoxymethane‐treated A/J mice , 2006, International journal of cancer.

[71]  T. Ohkusa,et al.  Promotion of colorectal neoplasia in experimental murine ulcerative colitis. , 1996, Gut.

[72]  T. Sugimura,et al.  Suppression of azoxymethane-induced colonic aberrant crypt foci by a nitric oxide synthase inhibitor. , 2000, Cancer letters.

[73]  Y. Whang,et al.  p38 and EGF receptor kinase-mediated activation of the phosphatidylinositol 3-kinase/Akt pathway is required for Zn2+-induced cyclooxygenase-2 expression. , 2005, American journal of physiology. Lung cellular and molecular physiology.

[74]  A. Forbes,et al.  Thirty-year analysis of a colonoscopic surveillance program for neoplasia in ulcerative colitis. , 2006, Gastroenterology.

[75]  V. Steele,et al.  Nitric oxide–releasing aspirin and indomethacin are potent inhibitors against colon cancer in azoxymethane-treated rats: effects on molecular targets , 2006, Molecular Cancer Therapeutics.

[76]  G. Abrams,et al.  CELLULAR RENEWAL AND MUCOSAL MORPHOLOGY IN EXPERIMENTAL ENTERITIS. INFECTION WITH SALMONELLA TYPHIMURIUM IN THE MOUSE. , 1963, Laboratory investigation; a journal of technical methods and pathology.

[77]  M. Bronner,et al.  The role of cyclooxygenase 2 in ulcerative colitis-associated neoplasia. , 2000, The American journal of pathology.

[78]  G. T. te Meerman,et al.  Association Between Toll‐like Receptor 4 and Inflammatory Bowel Disease , 2005, Inflammatory bowel diseases.

[79]  C. Janeway,et al.  MyD88 is an adaptor protein in the hToll/IL-1 receptor family signaling pathways. , 1998, Molecular cell.

[80]  T. Fujioka Clarithromycin resistance in Helicobacter pylori: implications for therapy , 2000, Journal of Gastroenterology.

[81]  Osamu Takeuchi,et al.  Maturation of Human Dendritic Cells by Cell Wall Skeleton of Mycobacterium bovis Bacillus Calmette-Guérin: Involvement of Toll-Like Receptors , 2000, Infection and Immunity.

[82]  A. Crispin,et al.  The Role of Toll‐like Receptor 4 Asp299Gly and Thr399Ile Polymorphisms and CARD15/NOD2 Mutations in the Susceptibility and Phenotype of Crohn's Disease , 2005, Inflammatory bowel diseases.

[83]  J. Terdiman,et al.  Effect of 5-Aminosalicylate Use on Colorectal Cancer and Dysplasia Risk: A Systematic Review and Metaanalysis of Observational Studies , 2005, The American Journal of Gastroenterology.

[84]  C. Pothoulakis,et al.  Pathophysiological role of Toll-like receptor 5 engagement by bacterial flagellin in colonic inflammation. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[85]  S. Solomon,et al.  Celecoxib for the prevention of colorectal adenomatous polyps. , 2006, The New England journal of medicine.

[86]  C. Jefferies,et al.  Mal and MyD88: adapter proteins involved in signal transduction by Toll-like receptors , 2003, Journal of endotoxin research.

[87]  J. Glas,et al.  Crohn's disease is associated with a toll-like receptor-9 polymorphism. , 2004, Gastroenterology.

[88]  G. Laqueur,et al.  Comparison of the carcinogenicity of methylazoxymethanol-beta-D-glucosiduronic acid in conventional and germfree Sprague-Dawley rats. , 1981, Journal of the National Cancer Institute.

[89]  R. DuBois,et al.  Prostaglandin E2 Regulates Cell Migration via the Intracellular Activation of the Epidermal Growth Factor Receptor* , 2003, Journal of Biological Chemistry.

[90]  S. Akira,et al.  Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis. , 2004, Gastroenterology.

[91]  Jongdae Lee,et al.  Immunostimulatory DNA ameliorates experimental and spontaneous murine colitis. , 2002, Gastroenterology.

[92]  Benjamin P. Westover,et al.  Glycan Foraging in Vivo by an Intestine-Adapted Bacterial Symbiont , 2005, Science.

[93]  I. Singer,et al.  Cyclooxygenase 2 is induced in colonic epithelial cells in inflammatory bowel disease. , 1998, Gastroenterology.

[94]  J. Terzic,et al.  Microsatelite GT polymorphism in the toll‐like receptor 2 is associated with colorectal cancer , 2006, Clinical genetics.